1337P The clincial utility of circulating free DNA (cfDNA) analysis in non-small cell lung cancer (NSCLC) in the United Kingdom

Greystoke, Alastair; Carter, Mathew; Griffiths, Wyn; Laviste, Glenda; Ortega-Franco, Ana; Rafee, Shereen; Hannaway, Nicola; Bridgewood, A.; Hall, Srr; Blackhall, Fiona

doi:10.1016/j.annonc.2020.08.1651

Annals of Oncology

2020

DOI: 10.1016/j.annonc.2020.08.1651

|View full text |Cite

1337P The clincial utility of circulating free DNA (cfDNA) analysis in non-small cell lung cancer (NSCLC) in the United Kingdom

Alastair Greystoke

Mathew Carter

Wyn Griffiths

et al.

Abstract: Conclusions: Our study showed the prevalence of HER2 alterations in Chinese NSCLC patients was 4.4%, and revealed the poor efficacy of immunotherapy in NSCLC patients harboring HER2 mutations.Legal entity responsible for the study: Zhejiang Cancer Hospital.

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

1337P The clincial utility of circulating free DNA (cfDNA) analysis in non-small cell lung cancer (NSCLC) in the United Kingdom

Abstract: Conclusions: Our study showed the prevalence of HER2 alterations in Chinese NSCLC patients was 4.4%, and revealed the poor efficacy of immunotherapy in NSCLC patients harboring HER2 mutations.Legal entity responsible for the study: Zhejiang Cancer Hospital.

This publication either has no citations yet, or we are still processing them

See others like this or search for similar articles

Contact Info

Product

Resources

About